Vaccine slashes illness in kids

Hospitalizations drop dramatically

By Marilynn Marchione **Associated Press**

WASHINGTON — A vaccine against rotavirus, the leading cause of diarrhea in infants, has led to a dramatic drop in hospitalization and emergency room visits since it came on the market two years ago, doctors reported yesterday.

A bonus: The vaccine seems to be preventing illness even in unvaccinated children by cutting the number of infections in the community that kids can pick up

"We're a little surprised by the degree of impact given the coverage we've achieved," said Jane Seward of the federal Centers for Disease Control and Prevention. Only about half of young children had received the vaccine and very few had received all three doses when the studies were done.

Results were reported at an infectious diseases conference in Washington.

Before the vaccine, more than 200,000 U.S. children were taken to emergency rooms and more than 55,000 were hospitalized each year with rotavirus, which causes vomiting and diarrhea, mostly from January through May. Worldwide, the virus kills 1,600 young children each day.

Since Merck & Co.'s Rotateq came out in 2006, hospital visits and stays because of the virus have dropped 80 percent to 100 percent, studies by the CDC and several other groups show.

Last winter, rotavirus cases started and peaked two to three months later and were much less extensive than in previous years, CDC scientists report. Hospitals in a network that tracks these cases for the CDC saw more than an 80 percent drop in admissions from them, one study show-

Another study, by Merck, found a 100 percent drop in hospitalizations and ER visits during the 2007 and 2008 rotavirus seasons compared to previous ones. The study was based on a review of health-insurance claims for about 61,000 infants and diagnoses by doctors in routine clinical practice.

Rotateq is an oral vaccine given at 2, 4 and 6 months of age. In June, a second rotavirus vaccine came on the market — GlaxoSmith-Kline's Rotarix. It requires only two doses, completed by 4 months of age.

Also at the conference, scientists reported that a new version of Wyeth's Prevnar vaccine seems to better protect kids against germs that cause pneumonia, meningitis and ear infections, but whether it makes it onto the market before dangerous strains become a big problem remains to be

Scientists have been retooling Prevnar, which came on the market in 2000 and is advised for children under age 2. It protects against the seven strains of Strep bacteria that were causing the most serious infections at the time. Since then, new strains have become more of a threat and increasingly are resistant to common antibiotics.